Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (192${count})

  • Therapeutic Pipeline Program, 2014
    Development of a mGluR4 Therapeutic for Parkinson's Disease

    Study Rationale: 
    One of the major objectives for the development of new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through levodopa and...

  • Research Grant, 2013
    A New Pharmaceutical Target for Mono and Add-on Therapy in Parkinson’s Disease

    Objective/Rationale:             
    We are targeting a molecule, for the first time in Parkinson’s research, that is only present in the human brain’s motor circuitry and that we believe will respond to...

  • Fast Track, 2002
    Comparitive gene expression analysis of the brain in Parkinson's Disease and in familial encephalopathy with neuroserpin inclusion bodies (FENIB): implications for pathogenesis

    Parkinson's disease (PD) is a common neurological disorder that affects the control of movement and frequently cognition. Examination of postmortem brain tissue from subjects with Parkinson's disease...

  • Research Grant, 2024
    Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease

    Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...

  • Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021
    Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease

    Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...

  • Analysis of Patient-Reported Outcomes from Fox Insight, 2021
    Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease

    Study Rationale:    
    The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, indicating differences in the underlying disease process that may also be...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.